Spyre Therapeutics, Inc. (SYRE) stock analysis

In our weekly check, Spyre Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13.

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SYRE.

What our checks show for SYRE

Red flags

Warning signs

Strengths

Similar companies

MDGL · TGTX · PCVX · PRAX · KRYS · KYMR

Questions

What grade does Spyre Therapeutics, Inc. (SYRE) have?

In our weekly check, Spyre Therapeutics, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of SYRE stock?

This week's biggest flags for Spyre Therapeutics, Inc.: Gross margin falling, Weak EPS forecast, Weak revenue forecast. In total 15 of 22 checks show a warning or a red flag.

What does Spyre Therapeutics, Inc. do?

Spyre Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as SYRE.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis